Israel Englander Terns Pharmaceuticals, Inc. Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 1,578,534 shares of TERN stock, worth $8.84 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,578,534

Previous 1,140,392 38.42%

Holding current value

$8.84 Million

Previous $7.77 Million 69.51%

% of portfolio

0.01%

Previous 0.0%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$6.49 - $10.8 $2.84 Million - $4.73 Million	438,142 Added 38.42%	1,578,534 $13.2 Million
Q2 2024 Aug 14, 2024	SELL	$4.54 - $8.2 $10.4 Million - $18.8 Million	-2,292,400 Reduced 66.78%	1,140,392 $7.77 Million
Q1 2024 May 15, 2024	BUY	$4.86 - $8.19 $7.02 Million - $11.8 Million	1,444,151 Added 72.62%	3,432,792 $22.5 Million
Q4 2023 Feb 14, 2024	SELL	$3.37 - $6.86 $989,435 - $2.01 Million	-293,601 Reduced 12.86%	1,988,641 $12.9 Million
Q2 2023 Aug 14, 2023	BUY	$7.35 - $13.29 $8.82 Million - $15.9 Million	1,199,859 Added 110.85%	2,282,242 $20 Million
Q1 2023 May 15, 2023	SELL	$7.91 - $12.0 $2.96 Million - $4.5 Million	-374,822 Reduced 25.72%	1,082,383 $12.8 Million
Q4 2022 Feb 14, 2023	BUY	$4.62 - $10.18 $4.96 Million - $10.9 Million	1,074,492 Added 280.76%	1,457,205 $14.8 Million
Q3 2022 Nov 14, 2022	BUY	$1.87 - $6.42 $196,396 - $674,260	105,025 Added 37.82%	382,713 $2.25 Million

Others Institutions Holding TERN

# of Institutions

167

Shares Held

78.3M

Call Options Held

580K

Put Options Held

454K

View Full List

About Terns Pharmaceuticals, Inc.

Ticker TERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,613,800
Market Cap $211M
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...

More about TERN

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account